Replimune Group (NASDAQ:REPL) CFO Sells $132,175.68 in Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 9,256 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $14.28, for a total value of $132,175.68. Following the transaction, the chief financial officer directly owned 215,852 shares in the company, valued at $3,082,366.56. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emily Luisa Hill also recently made the following trade(s):

• On Monday, August 10th, Emily Luisa Hill sold 11,448 shares of Replimune Group stock. The stock was sold at an average price of $12.97, for a total value of $148,480.56.

Replimune Group Stock Up 5.1%

REPL stock opened at $14.77 on Friday. The business’s 50 day simple moving average is $11.25 and its 200 day simple moving average is $8.05. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $15.70. The firm has a market capitalization of $1.39 billion, a PE ratio of -4.69 and a beta of 0.88. The company has a current ratio of 5.23, a quick ratio of 4.79 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). As a group, research analysts anticipate that Replimune Group, Inc. will post -2.78 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Weiss Ratings lowered shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Tuesday, June 30th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a research report on Wednesday, August 12th. Finally, Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.86.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently added to or reduced their stakes in REPL. International Assets Investment Management LLC acquired a new position in Replimune Group in the 4th quarter valued at $29,000. CWM LLC grew its holdings in shares of Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares in the last quarter. Allworth Financial LP acquired a new stake in shares of Replimune Group during the 2nd quarter worth $62,000. Essential Partners LLC increased its position in shares of Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after purchasing an additional 5,624 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.